Investor

Neurimmune

Last cheque observed Sep 2026; 1 cheques on record.

Deploying nowGrowth equity

Series B

Deploying now
100%of best year1cheques in 12 months, 1 on record
Since the last cheque54days00hrs00min00sec
Median round$30MRounds led1 of 1
Pitch Neurimmune

Neurimmune highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series B: 100% of its rounds

  3. 03

    Led 1 rounds

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first1 appearances

  1. 2026

    1 round

  2. Sept

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Recently backed

The latest companies Neurimmune put money into.

Quick answers about Neurimmune

What does Neurimmune invest in?

Neurimmune invests most often at Series B (100% of the rounds on record).

How active is Neurimmune?

1 investments on record, 1 of them in the last 12 months, and it led 1. The most recent was in Sept 2026.

What has Neurimmune invested in recently?

Its most recent investments on record: NovaGo Therapeutics (Series B, Sept 2026).

How big are Neurimmune's cheques?

The median round it joins is $30M.

Is Neurimmune investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

What kind of investor is Neurimmune?

Neurimmune is a growth equity firm.

Where does this information on Neurimmune come from?

From 3 articles and filings naming it in a round, public registers and its own website, checked and rebuilt every night.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it